Tuberculosis: a promising vaccine candidate

Scientists from the Institut Pasteur, working in collaboration with a team from Italy, have published the results of their research into the action mechanisms of a promising experimental tuberculosis (TB) vaccine in the journal PLOS Pathogens. BCG, the only currently approved TB vaccine, has been around for almost a century, but it is only partially effective and the protection it offers fades over time. Given the current emergence of adult TB cases in conjunction with the HIV epidemic and the rise in multidrug-resistant TB strains, the development of a new, more effective vaccine is a global health priority. This research was conducted in connection with the TBVAC2020 European consortium.

To find out more, read the press release